Scailyte Quarterly Update, January 2021

VACANCY: Director of Biomarker Discovery

Read more

Scailyte and Geninus announce a strategic partnership to develop a predictive assay for immune-checkpoint inhibitors in Non-Small Cell Lung Cancer patients

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cel

Read more

Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis

Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today

Read more

Scailyte Quarterly Update, January 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

ScaiVision® performs best-in-class at sample class prediction!

ScaiVision® v1.0.0 was released internally and benchmarked in a massive experiment, outperforming a

Read more

Scailyte participates @ swissnex san francisco DEMO DAY!

Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day

Read more

Scailyte Q3 2020 Update

Q3 2020 update on Scailyte's progress towards its mission to save millions of lives.

Read more

ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.

As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,

Read more